Conducting clinical trials in rare diseases and advancing research pipelines requires a collaborative, multi-stakeholder approach. This process requires cooperation from industry, academic researchers, advocacy groups, and patients as well as their caregivers and families. In this white paper, we look at the barriers drug developers face when positioning a new trial in the rare disease space and how to minimize these barriers by applying a multi-stakeholder collaborative approach to drug development.
Clinical Trial Manager
A PRA Clinical Trial Manager leads and manages the execution of one or more clinical studies from study startup through database release. As a core…
Program Challenges Strengthen Partnership
PRA Health Sciences was selected to conduct a global program of studies that targeted 2,200+ patients with multiple sclerosis (MS). Although there…
About PRA Health Sciences
We are a global healthcare intelligence partner, consistently ranked among the top CROs and best employers worldwide.